MindGenix

A-β Deposition in APP/PS1

1. Holcomb L., Gordon M., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C., Eckman C., Younkin S., Hsiao K., Duff K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature. Med, 4: 97-100

2. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon, S.E., Wang R., Mann D., Dickson D., Duff K. (1999) Amyloid phenotype characterization of transgenic mice over-expressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis., 6 (4), 231-244

3. Wengenack B., Whelan S., Curran G.L., Duff K. and Poduslo J.F. (2000) Quantitative Histological Analysis of Alzheimer's Amyloid Deposition in APP, PS1 Transgenic Mouse. Neuroscience, 101(4): 939-944

4. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. (2001) Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging.22(3):377-85.

5. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. (2002) Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab. 22(2):223-31.

6. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K. (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res. 110(1):119-25.

7. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH ( 2003) Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med. 50(2):293-302.

8. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, Morgan DG, Morgan TE, Finch CE (2004) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging. 26(7):995-1000.

9. Helpern JA, Lee SP, Falangola MF, Dyakin VV, Bogart A, Ardekani B, Duff K, Branch C, Wisniewski T, de Leon MJ, Wolf O, O'Shea J, Nixon RA (2004). MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med. 51(4):794-8.

10. Lee SP, Falangola MF, Nixon RA, Duff K, Helpern JA (2004). Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med.52(3):538-44.

11. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA (2005). Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res. 30(2):201-5.

12. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Claudio Cuello A (2005). The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 27(11):1644-57.

13. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM (2006). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 281(34):24566-74.

Changes in Behavior and Synaptic Function in APP/PS1

14. Holcomb L.A., Gordon M.N., Jantzen P., Hsiao K., Duff K. & Morgan D. (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet., 29(3): 177-185

15. Arendash W.A., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E. & Diamond D.M. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res., 891: 42-53.

16. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., Hatcher J.M., DiCarlo G., Gottschall W.P.E., Morgan D. & Arendash G.W. (2001). Correlation between cognitive deficits and Ab deposits in transgenic APP+PS1 mice. Neurobiology of Aging, 22: 377-386.

17. Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, McKinney M.(2001) Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport. 12(7):1377-84.

18. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, Stanley HE, Irizarry MC, Hyman BT (2002). Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci U S A. 29;99(22):13990-5.

19. Dickey CA, Loring JF, Montgomery JGordon MN, Eastman PS Morgan D. (2003) Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci. 15;23(12):5219-26.

20. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, Morgan D.(2003) Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci. 2003 Jun;6(3):153-62.

21. Dickey CA, Gordon MN, Mason JE, Wilson NJ, Diamond DM, Guzowski JF, Morgan D. (2004) Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem. 88(2):434-42.

22. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T. (2004) Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol. 63(5):418-28.

23. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment J Clin Invest. 14(11):1624-34.

24. Dickey CA, Gordon MN, Wilcock DM, Herber DL, Freeman MJ, Morgan D. (2005) Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci.6(1):7.

25. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW. (2006) Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis.;23(2):351-61.

26. Ewers M, Morgan DG, Gordon MN, Woodruff-Pak DS.(2006) Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiol Aging. 2006 Aug;27(8):1118-28.

27. Lansbury PT Jr. (2006) Improving synaptic function in a mouse model of AD. Cell. 25;126(4):655-7.

28. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006 Aug 25;126(4):775-88.

29. Zhang H, Gong B, Liu S, Fa' M, Ninan I, Staniszewski A, Arancio O. Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res. 2005 Apr;2(2):137-40.

Neuropathology of APP/PS1

30. Wong T.P., Debeir T., Duff K. & Cuello A.C. (1999) Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci., 1,19 (7): 2706-2716.

31. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., Mann D.M.A., Hyman B.T. & Iwatsubo T. (2000) Age-related amyloid _ deposition in transgenic mice overexpressing both Alzheimer mutant Presenilin 1 and Amyloid _ precursor Protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol., 157(1): 331-339

32. Matsuoka Y, Picciano M, La Francois J, Duff K. (2001). Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience. 2001;104(3):609-13.

33. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol., 158(4): 1345-1354

34. Le R., Cruz L., Urbanc B., Hsiao-Ashe K., Duff K., Irizarry M.C., Stanley H.E. & Hyman B.T. (2001). Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer's disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol., 60(8): 753-758

35. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K. & McKinney M. (2001). Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Molecular Neuroscience, 12(7): 1377-1384

36. Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, Mufson EJ. (2001) Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol. 170(2):227-43.

37. Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H. & Howlett D.R. (2001) Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol., 171: 59-71

38. Chaudhury AR, Gerecke KM, Wyss JM, Morgan DG, Gordon MN, Carroll SL. (2003) Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol. 62(1):42-54.

39. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. (2004). Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 55(6):801-14.

40. Tsai J, Grutzendler J, Duff K, Gan WB. (2004) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci.7(11):1181-3.

41. Herber DL, Severance EG, Cuevas J, Morgan D, Gordon MN. (2004) Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem.52(10):1367-76.

42. Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. (2004). Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 33(3):377-87.

43. Soreghan BA, Lu BW, Thomas SN, Duff K, Rakhmatulin EA, Nikolskaya T, Chen T, Yang AJ. (2005)Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimer's disease. J Alzheimers Dis.8(3):227-41.

44. Karlnoski R, Wilcock D, Dickey C, Ronan V, Gordon MN, Zhang W, Morgan D, Taglialatela G. (2007) Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiol Dis. 25(1):179-88.

Vascular and BBB Changes in APP/PS1

45. Poduslo J.F., Curran G.L., Wengenack T.M., Malester B. & Duff K. (2001). Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8: 555-567

46. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. (2005). Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 313(3):1370-8.

47. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C. (2005).Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol. 167(2):527-43.

Amyloid modulating agents in APP/PS1

48. Morgan D., Diamond D., Gottschall P., Ugen K., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M. and Arendash G. (2000). A_ Peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408: 982-985.

49. Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. (2001). Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 20(11):731-6.

50. Refolo L., Pappolla M., Malester B., LaFrancois J., Wang R., Tint G., Sambamurti K., Bryant-Thomas T. and Duff. K. (2000) Hypercholesterolemia accelerates amyloid pathology in a transgenic mouse model for Alzheimer's disease amyloidosis. Neurobiol. Dis., 7(4): 321-331

51. Refolo L. M., Pappolla M. A., LaFrancois J., Malester B., Schmidt S. D., Thomas-Bryant T., Tint G. S., Wang R., Mercken M., Petanceska S.S. & Duff K.E. (2001). A Cholesterol-lowering drug reduces b-Amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8: 890�899

52. Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo G, Wilcock D, Morgan D. (2001). Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 20(11):737-44.

53. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. (2001) Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging. 22(6):1007-12.

54. Di Rosa G, Odrijin T, Nixon RA, Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):135-41.

55. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. (2002). Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 15;22(6):2246-54.

56. Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. (2003). Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav Neurosci. 117(3):478-84.

57. Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, Morgan D, Gordon MN. (2003). Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res. 28(1):83-93.

58. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O. (2003). Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci. 20(3):357-62.

59. Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW. (2005). Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience. 130(3):667-84.



	A-β Deposition in APP/PS1 1. Holcomb L., Gordon M., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C., Eckman C., Younkin S., Hsiao K., Duff K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature. Med, 4: 97-100 2. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon, S.E., Wang R., Mann D., Dickson D., Duff K. (1999) Amyloid phenotype characterization of transgenic mice over-expressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis., 6 (4), 231-244 3. Wengenack B., Whelan S., Curran G.L., Duff K. and Poduslo J.F. (2000) Quantitative Histological Analysis of Alzheimer's Amyloid Deposition in APP, PS1 Transgenic Mouse. Neuroscience, 101(4): 939-944 4. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. (2001) Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging.22(3):377-85. 5. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. (2002) Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab. 22(2):223-31. 6. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K. (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res. 110(1):119-25. 7. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH ( 2003) Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med. 50(2):293-302. 8. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, Morgan DG, Morgan TE, Finch CE (2004) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging. 26(7):995-1000. 9. Helpern JA, Lee SP, Falangola MF, Dyakin VV, Bogart A, Ardekani B, Duff K, Branch C, Wisniewski T, de Leon MJ, Wolf O, O'Shea J, Nixon RA (2004). MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med. 51(4):794-8. 10. Lee SP, Falangola MF, Nixon RA, Duff K, Helpern JA (2004). Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med.52(3):538-44. 11. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA (2005). Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res. 30(2):201-5. 12. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Claudio Cuello A (2005). The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 27(11):1644-57. 13. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM (2006). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 281(34):24566-74. Changes in Behavior and Synaptic Function in APP/PS1 14. Holcomb L.A., Gordon M.N., Jantzen P., Hsiao K., Duff K. & Morgan D. (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet., 29(3): 177-185 15. Arendash W.A., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E. & Diamond D.M. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res., 891: 42-53. 16. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., Hatcher J.M., DiCarlo G., Gottschall W.P.E., Morgan D. & Arendash G.W. (2001). Correlation between cognitive deficits and Ab deposits in transgenic APP+PS1 mice. Neurobiology of Aging, 22: 377-386. 17. Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, McKinney M.(2001) Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport. 12(7):1377-84. 18. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, Stanley HE, Irizarry MC, Hyman BT (2002). Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci U S A. 29;99(22):13990-5. 19. Dickey CA, Loring JF, Montgomery JGordon MN, Eastman PS Morgan D. (2003) Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci. 15;23(12):5219-26. 20. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, Morgan D.(2003) Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci. 2003 Jun;6(3):153-62. 21. Dickey CA, Gordon MN, Mason JE, Wilson NJ, Diamond DM, Guzowski JF, Morgan D. (2004) Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem. 88(2):434-42. 22. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T. (2004) Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol. 63(5):418-28. 23. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment J Clin Invest. 14(11):1624-34. 24. Dickey CA, Gordon MN, Wilcock DM, Herber DL, Freeman MJ, Morgan D. (2005) Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci.6(1):7. 25. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW. (2006) Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis.;23(2):351-61. 26. Ewers M, Morgan DG, Gordon MN, Woodruff-Pak DS.(2006) Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiol Aging. 2006 Aug;27(8):1118-28. 27. Lansbury PT Jr. (2006) Improving synaptic function in a mouse model of AD. Cell. 25;126(4):655-7. 28. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006 Aug 25;126(4):775-88. 29. Zhang H, Gong B, Liu S, Fa' M, Ninan I, Staniszewski A, Arancio O. Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res. 2005 Apr;2(2):137-40. Neuropathology of APP/PS1 30. Wong T.P., Debeir T., Duff K. & Cuello A.C. (1999) Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci., 1,19 (7): 2706-2716. 31. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., Mann D.M.A., Hyman B.T. & Iwatsubo T. (2000) Age-related amyloid _ deposition in transgenic mice overexpressing both Alzheimer mutant Presenilin 1 and Amyloid _ precursor Protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol., 157(1): 331-339 32. Matsuoka Y, Picciano M, La Francois J, Duff K. (2001). Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience. 2001;104(3):609-13. 33. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol., 158(4): 1345-1354 34. Le R., Cruz L., Urbanc B., Hsiao-Ashe K., Duff K., Irizarry M.C., Stanley H.E. & Hyman B.T. (2001). Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer's disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol., 60(8): 753-758 35. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K. & McKinney M. (2001). Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Molecular Neuroscience, 12(7): 1377-1384 36. Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, Mufson EJ. (2001) Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol. 170(2):227-43. 37. Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H. & Howlett D.R. (2001) Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol., 171: 59-71 38. Chaudhury AR, Gerecke KM, Wyss JM, Morgan DG, Gordon MN, Carroll SL. (2003) Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol. 62(1):42-54. 39. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. (2004). Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 55(6):801-14. 40. Tsai J, Grutzendler J, Duff K, Gan WB. (2004) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci.7(11):1181-3. 41. Herber DL, Severance EG, Cuevas J, Morgan D, Gordon MN. (2004) Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem.52(10):1367-76. 42. Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. (2004). Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 33(3):377-87. 43. Soreghan BA, Lu BW, Thomas SN, Duff K, Rakhmatulin EA, Nikolskaya T, Chen T, Yang AJ. (2005)Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimer's disease. J Alzheimers Dis.8(3):227-41. 44. Karlnoski R, Wilcock D, Dickey C, Ronan V, Gordon MN, Zhang W, Morgan D, Taglialatela G. (2007) Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiol Dis. 25(1):179-88. Vascular and BBB Changes in APP/PS1 45. Poduslo J.F., Curran G.L., Wengenack T.M., Malester B. & Duff K. (2001). Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8: 555-567 46. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. (2005). Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 313(3):1370-8. 47. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C. (2005).Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol. 167(2):527-43. Amyloid modulating agents in APP/PS1 48. Morgan D., Diamond D., Gottschall P., Ugen K., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M. and Arendash G. (2000). A_ Peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408: 982-985. 49. Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. (2001). Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 20(11):731-6. 50. Refolo L., Pappolla M., Malester B., LaFrancois J., Wang R., Tint G., Sambamurti K., Bryant-Thomas T. and Duff. K. (2000) Hypercholesterolemia accelerates amyloid pathology in a transgenic mouse model for Alzheimer's disease amyloidosis. Neurobiol. Dis., 7(4): 321-331 51. Refolo L. M., Pappolla M. A., LaFrancois J., Malester B., Schmidt S. D., Thomas-Bryant T., Tint G. S., Wang R., Mercken M., Petanceska S.S. & Duff K.E. (2001). A Cholesterol-lowering drug reduces b-Amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8: 890�899 52. Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo G, Wilcock D, Morgan D. (2001). Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 20(11):737-44. 53. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. (2001) Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging. 22(6):1007-12. 54. Di Rosa G, Odrijin T, Nixon RA, Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):135-41. 55. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. (2002). Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 15;22(6):2246-54. 56. Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. (2003). Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav Neurosci. 117(3):478-84. 57. Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, Morgan D, Gordon MN. (2003). Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res. 28(1):83-93. 58. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O. (2003). Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci. 20(3):357-62. 59. Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW. (2005). Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience. 130(3):667-84.

	Home \| The Team \| The PS1/APP Advantage \| Bibliography News & Events \| Services \| Contact Us Copyright 2007 MindGenix